Key Takeaways
- • CVC and Groupe Bruxelles Lambert (GBL) have launched a binding €10.7 billion (approximately $12.4 billion) takeover bid for Italian pharmaceutical company Recordati at €51.29 per share, seeking to delist the company from Euronext Milan.
- • CVC already controls 46.8% of Recordati through its Rossini holding company and has irrevocably committed to tender its shares; the consortium requires at least 66.67% voting stake to secure control.
- • Recordati's board is divided: six of ten directors backed the offer as fair value, while four independent directors opposed it, signaling potential shareholder resistance to the take-private transaction.
- • The deal includes co-investment from Abu Dhabi Investment Authority (ADIA) subsidiary Luxinva, Canada Pension Plan Investment Board (CPPIB), and Recordati's billionaire chairman Andrea Recordati, creating a "stable shareholder base" for long-term development.
- • Recordati management seeks privatization to accelerate M&A and licensing deals with greater confidentiality and faster decision-making, following 8.3% revenue growth to €2.62 billion in 2025 and a doubled sales forecast for lead asset Isturisa (osilodrostat) to €1.2 billion peak sales.
Summary
The consortium now includes prominent institutional capital: Abu Dhabi Investment Authority's Luxinva subsidiary, Canada Pension Plan Investment Board (CPPIB), and Recordati's executive chairman Andrea Recordati have all committed to the transaction. The bidders frame this as a "committed, flexible and stable shareholder base" with CVC and GBL acting as co-control investors pledging long-term support for company development. However, board consensus remains absent. According to Reuters, six of Recordati's ten directors endorsed the €51.29 per share offer as fair value, while four independent directors dissented, indicating meaningful shareholder resistance ahead of a formal vote.
Recordati's strategic rationale for privatization centers on operational flexibility. The company reported 2025 revenues of €2.62 billion, up 8.3% year-over-year, but management has indicated the need for capital to fund bolt-on acquisitions and licensing agreements. Private status would enable faster decision-making and enhanced confidentiality around M&A and partnership negotiations without public market scrutiny. This consideration follows Recordati's decision to double the peak sales forecast for Isturisa (osilodrostat), its Cushing's syndrome therapy, from €600 million to €1.2 billion—a significant upside revision that could increase valuation expectations among public shareholders and complicate deal dynamics.
The transaction requires shareholder approval, specifically a minimum 66.67% voting stake to secure full control and delisting. The board's internal division, combined with the independent directors' opposition, suggests the bid may face resistance from minority shareholders who may perceive undervaluation relative to Recordati's recent operational momentum and product pipeline potential.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.